Introduction: The rationale for mass screening for prostate cancer remains controversial. Apart from the scientific debate, we wanted to evaluate the opinion of prostate cancer screening candidates concerning the practical modalities of this screening and assess the impact of various personal, medical or social factors on their replies.
Material And Method: Following a screening campaign in a French district, 1,774 men, 50 to 70 years of age, who completed screening were interviewed by questionnaire concerning the duration, frequency, mode of blood sampling and the cost of screening. Medical history, family history and lifestyle were also evaluated.
Results: Among 1,774 candidates who returned an interpretable questionnaire during the screening campaign (participation rate: 31%), 27.1% of subjects interviewed declared that the personal financial cost would be an obstacle to screening, 5.1% considered that collection of a blood sample from the cubital fossa would be an obstacle to screening, 6.5% considered that one PSA per year was too frequent, and 8.1% considered that screening between the ages of 50 and 70 years was too long.
Conclusion: More than 90% of men who participated in a prostate cancer screening campaign appear to be in favour of continuation of screening according to the current modalities provided it is free of charge. The acceptance rate was better for men with a family history of prostate cancer, men who had already had a PSA assay, men living alone and men under 60 years of age.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1166-7087(07)92392-1 | DOI Listing |
J Transl Med
January 2025
Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan, Wuhan, 430030, P.R. China.
Introduction: Prostate cancer is one of the most common cancers in the United States with a high mortality rate. In recent years, the traditional opinion about prostate microbiome was challenged. Although there still are some arguments, an escalating number of researchers are shifting their focus toward the microbiome within the prostate tumor environment.
View Article and Find Full Text PDFMol Med
January 2025
Department of Urology, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, 510920, Guangdong, People's Republic of China.
Prostate cancer (PCa) is a highly common type of malignancy and affects millions of men in the world since it is easy to recur or emerge therapy resistance. Therefore, it is urgent to find novel treatments for PCa patients. In the current study, we found that tegaserod maleate (TM), an FDA-approved agent, inhibited proliferation, colony formation, migration as well as invasion, caused the arrest of the cell cycle, and promoted apoptosis of PCa cells in vitro.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Pharmaceutics, College of Pharmacy, King Saud University, PO Box 2457, Riyadh, 11451, Saudi Arabia.
Prostate cancer presents a major health issue, with its progression influenced by intricate molecular factors. Notably, the interplay between miRNAs and changes in transcriptomic patterns is not fully understood. Our study seeks to bridge this knowledge gap, employing computational techniques to explore how miRNAs and transcriptomic alterations jointly regulate the development of prostate cancer.
View Article and Find Full Text PDFInsights Imaging
January 2025
Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Purposes: The presence of clinically significant prostate cancer (csPCa) is equivocal for patients with prostate imaging reporting and data system (PI-RADS) category 3. We aim to develop deep learning models for re-stratify risks in PI-RADS category 3 patients.
Methods: This retrospective study included a bi-parametric MRI of 1567 consecutive male patients from six centers (Centers 1-6) between Jan 2015 and Dec 2020.
Eur J Drug Metab Pharmacokinet
January 2025
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Background And Objective: A gonadotropin-releasing hormone (GnRH) agonist such as leuprolide is widely used to achieve sustained suppression of testosterone levels, which play a critical role in the treatment of prostate cancer. Recent advances in drug delivery systems have led to the development of long-acting depot formulations, such as the 6-month intramuscular (IM) leuprolide formulation, which aim to simplify dosing and improve convenience for both patients and healthcare providers. Exploring extended dosing intervals for such formulations represents a promising approach to further optimize treatment regimens, potentially balancing efficacy with patient-centered care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!